Keyhole surgery in the womb could fix spinal defects with fewer risks
NCT ID NCT02230072
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests a new, minimally invasive surgical technique to repair open neural tube defects (spina bifida) in unborn babies. Instead of opening the uterus, surgeons use a tiny camera and tools inserted through small incisions. The goal is to close the spinal defect effectively while lowering risks like uterine rupture and premature birth. Pregnant women carrying a single fetus with a spinal defect between T1 and S1 and signs of Chiari II malformation may be eligible.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- fetoscopy (minimally invasive surgical device)
- What this could lead to
- If successful, this technique could offer a safer way to repair fetal spinal defects, potentially reducing complications like uterine rupture and allowing vaginal delivery.
- What could go wrong
- This is an early-phase trial with only 60 participants, so the procedure may not prove safer or as effective as open surgery. Risks include preterm birth or membrane rupture.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jul 2014
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Pregnant women - maternal age 18 years or older and capable of consenting for their own participation in this study, 2. Singleton pregnancy, 3. MMC with the upper boundary located between T1 and S1, 4. Evidence of hindbrain herniation (confirmed on MRI to have an Arnold-Chiari type II malformation), 5. Absence of chromosomal abnormalities and associated anomalies, 6. Gestational age at the time of the procedure will be between 19 0/7 weeks and 25 6/7 weeks, 7. Normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing (amniocentesis or CVS). If there is a balanced translocation with normal MCA with no other anomalies the candidate can be included. Patients declining invasive testing will be excluded. 8. Family has considered and declined the option of termination of the pregnancy at less than 24 weeks, 9. Family meets psychosocial criteria (sufficient social support, ability to understand requirements of the study), and 10. Parental/guardian permission (informed consent) for follow up of child after birth. Exclusion Criteria: 1. Fetal anomaly unrelated to MMC, 2. Severe kyphosis, 3. Increased risk for preterm labor including short cervical length (\<1.5 cm), history of incompetent cervix with or without cerclage, and previous preterm birth, 4. Placental abnormalities (previa, abruption, accreta) known at time of enrollment, 5. A pre-pregnancy body-mass index ≥40, 6. Contraindications to surgery including previous hysterotomy (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) in active uterine segment, 7. Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, and uterine anomalies, 8. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy, 9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment, 10. Maternal medical condition that is a contraindication to surgery or anesthesia, 11. Low amniotic fluid volume (Amniotic Fluid Index less than 6cm) if deemed to be due to fetal anomaly, poor placental perfusion or function, or membrane rupture. Low amniotic fluid volume that responds to maternal hydration is not an exclusion criterion, 12. Patient does not have a support person (e.g. Spouse, partner, mother) available to support the patient for the duration of the pregnancy, 13. Inability to comply with the travel and follow-up requirements of the trial, 14. Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy, and 15. Patient scores as severely depressed on the BDI-II questionnaire; a score of 29 or above. 16. Maternal hypersensitivity to collagen.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neural tube defect are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University: Lucille Packard's Childrens Hospital
Stanford, California, 94305, United States
-
Texas Childrens Hospital
Houston, Texas, 77030, United States